CLDI

Calidi Biotherapeutics (CLDI)

Calidi Biotherapeutics Inc

から:

Regulatory News

Text Search:

次の項目別のソート:

Non-Regulatory News

Showing the most relevant articles for your search:AMEX:CLDI

日付	受信時刻	ニュースソース	見出し	コード	企業名
2024/05/15	05 : 05	Business Wire	Calidi Biotherapeutics Reports First Quarter 2024 Operating and Financial Results	AMEX:CLDI	Calidi Biotherapeutics Inc
2024/05/01	20 : 00	Business Wire	Calidi Biotherapeutics Announces Upcoming Presentations at the 2024 ASCO Annual Meeting	AMEX:CLDI	Calidi Biotherapeutics Inc
2024/04/23	20 : 00	Business Wire	Join Calidi Biotherapeutics’ Exclusive Live Investor Webinar and Q&A Session on April 24	AMEX:CLDI	Calidi Biotherapeutics Inc
2024/04/20	05 : 05	Business Wire	Calidi Biotherapeutics, Inc. Announces Closing of $6.1 Million Public Offering	AMEX:CLDI	Calidi Biotherapeutics Inc
2024/04/16	21 : 31	Business Wire	Calidi Biotherapeutics, Inc. Announces Pricing of $6.1 Million Public Offering	AMEX:CLDI	Calidi Biotherapeutics Inc
2024/04/09	20 : 00	Business Wire	Calidi Biotherapeutics Presents New Data on the Mechanisms of Action for Virotherapy-Loaded Stem Cells Used in the Company’s Novel Immunotherapies at the AACR Annual Meeting 2024	AMEX:CLDI	Calidi Biotherapeutics Inc
2024/03/16	05 : 05	Business Wire	Calidi Biotherapeutics Reports Fourth Quarter and Full-Year 2023 Operating and Financial Results	AMEX:CLDI	Calidi Biotherapeutics Inc
2024/03/11	20 : 00	Business Wire	Calidi Biotherapeutics and City of Hope Announce Funding from the California Institute for Regenerative Medicine (CIRM) to Advance CLD-101 (NeuroNova) in Ovarian Cancer	AMEX:CLDI	Calidi Biotherapeutics Inc
2024/02/12	21 : 00	Business Wire	Calidi Biotherapeutics to Highlight Novel Systemic Enveloped Oncolytic Virotherapy Platform Designed to Target All Tumor Sites at Upcoming Conference	AMEX:CLDI	Calidi Biotherapeutics Inc
2024/01/08	21 : 00	Business Wire	Calidi Biotherapeutics Announces the Appointment of Three New Members to its Scientific and Medical Advisory Board	AMEX:CLDI	Calidi Biotherapeutics Inc
2023/12/13	21 : 00	Business Wire	Calidi Biotherapeutics Announces Presentation of Clinical Study for NeuroNova with Recurrent High Grade Glioma at the 8th Oncolytic Virotherapy Summit	AMEX:CLDI	Calidi Biotherapeutics Inc
2023/12/12	21 : 00	Business Wire	Calidi Biotherapeutics Announces Appointment of Pharmaceutical Industry Veteran David LaPré to its Board of Directors	AMEX:CLDI	Calidi Biotherapeutics Inc
2023/11/20	21 : 00	Business Wire	Calidi Biotherapeutics Announces Issuance of New U.S. Patent Covering Novel SuperNova Technology Platform and Updates Anticipated Clinical Milestones	AMEX:CLDI	Calidi Biotherapeutics Inc
2023/11/15	06 : 05	Business Wire	Calidi Biotherapeutics Reports Third Quarter 2023 Operating and Financial Results	AMEX:CLDI	Calidi Biotherapeutics Inc
2023/11/03	20 : 00	Business Wire	Calidi Biotherapeutics (NYSEAM: CLDI) Presents Data on CLD-201 Demonstrating Inhibition of Tumor Growth and Induction of Robust Anti-Tumor Immunity at the Society for Immunotherapy of Cancer’s 38th Annual Meeting (SITC 2023)	AMEX:CLDI	Calidi Biotherapeutics Inc
2023/11/01	20 : 00	Business Wire	Calidi Biotherapeutics Announces Key Leadership Promotions and New Board Appointment	AMEX:CLDI	Calidi Biotherapeutics Inc
2023/10/30	20 : 00	Business Wire	Calidi Biotherapeutics Announces Appointment of Andrew Jackson as Chief Financial Officer	AMEX:CLDI	Calidi Biotherapeutics Inc
2023/10/10	20 : 00	Business Wire	Calidi Biotherapeutics To Present New Preclinical Data Highlighting Cell-based Virotherapy (SuperNova) Platform Technology at SITC 2023	AMEX:CLDI	Calidi Biotherapeutics Inc
2023/09/13	18 : 50	Business Wire	Calidi Biotherapeutics Debuts as a Publicly Traded Company Focused on Arming the Immune System to Fight Cancer with a New Generation of Targeted Immunotherapies	AMEX:CLDI	Calidi Biotherapeutics Inc